Navigation Links
VisEn Launches New Cat B 750 Fast(TM) Fluorescence Molecular Imaging Agent at American Heart Association Meeting
Date:11/12/2009

ORLANDO, Fla., Nov. 12 /PRNewswire/ -- VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today the commercial launch of its new Cat B 750 FAST(TM) imaging agent for measuring and monitoring cathepsin B activity associated with disease progression and therapeutic response in vivo. Cathepsin B expression is well known as a key biomarker and therapeutic target in a range of diseases, including atherosclerosis, oncology, and arthritis. The new agent is expected to have a significant impact in cardiovascular disease research, and is being launched at the American Heart Association Scientific Sessions 2009 in Orlando.

Cathepsin B proteases play an important role in disease progression and host response in several disease areas, and are key biomarkers in assessing and characterizing disease states. The new Cat B 750 FAST(TM) agent is designed to complement in vitro and in vivo protease readouts from cell-based assays and VisEn's existing in vivo agent product lines, providing earlier imaging time points and narrower specificity profiles of cathepsin B within the cathepsin family of proteases.

The new Cat B 750 FAST(TM) agent represents an additional protease-sensing agent developed from VisEn's new FAST ("Fluorescent Activatable Sensor Technology") in vivo agent platform. FAST agents are based on high-performance activatable smaller molecules that combine advanced biomarker specificity with optimized biocompatibility and rapid pharmacokinetics. These benefits allow for precise measurement and monitoring of key disease biomarkers in vivo.

VisEn also announced the commercial availability of its ReninSense680 FAST(TM) agent for localized in vivo measurement of changes in renin-angiotensin system (RAS) involved in hypertension and some neurological diseases.

"We
'/>"/>

SOURCE VisEn Medical Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Fox Chase Cancer Center and VisEn Medical Announce Program to Advance First Clinical Trials of Novel Fluorescence Molecular Imaging Technologies
2. VisEn Molecular Imaging Technology Enables Key Insights Into Newly Discovered Biologic Pathway Published in SCIENCE
3. Iomai Launches Phase 1/2 Safety Study of Dose-Sparing Patch for Use With Pandemic Influenza Vaccine
4. Keeping the Data Center Clean: ATEN Launches Industry-First KVM Switches with Antimicrobial Nanocoating to Protect Products from Bacteria Surviving on Surfaces
5. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
6. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
7. Strategic Diagnostics Launches Initial Oncology-Targeted Antibody Reagent Catalog
8. deCODE Launches Phase II Clinical Testing of DG051 for the Prevention of Heart Attack
9. Premier Micronutrient Launches Supplement for Hearing Health
10. deCODE Launches deCODE MI(TM) -- A Test for a Major Genetic Risk Factor for Early-onset Heart Attack
11. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... N.Y. , Jan. 15, 2014 Sono-Tek Corporation (OTC ... months ended November 30, 2013, compared to sales of $2,202,000 ... 20%. Once again, this quarter has also shown growth over ... the first quarter of this fiscal year. Markets that experienced ...
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... RAPIDS, Mich. , Jan. 15, 2014 As health ... the flu virus, select Meijer pharmacies in Michigan ... strep throat to eligible patients, enabling Meijer pharmacists to administer ... strict protocol set by a physician participating in the study. ...
Breaking Medicine Technology:Sono-Tek Announces Third Quarter Results 2Sono-Tek Announces Third Quarter Results 3Sono-Tek Announces Third Quarter Results 4Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 2Meijer Pharmacy Offers Free Flu, Strep Testing as Influenza Cases Rise Across the Midwest 3
... 20 Radius Health ("Radius") announced today that it ... institutional financing round, increasing total Series C investment to ... company,s inception to $106.5 million. All existing institutional investors ... NVS Strategic Fund and including MPM Capital, The Wellcome ...
... Amgen,(Nasdaq: AMGN ) and Millennium: ... Company Limited (TSE: 4052), today announced that,enrollment in ... 706) in,combination with paclitaxel and carboplatin for the ... has been temporarily suspended,following a planned safety data ...
Cached Medicine Technology:Radius Raises Additional $15 Million, Increasing Second Private Equity Financing Round to $82.5 Million 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 2Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 3Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 4Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 5Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 6Amgen, Takeda and Millennium Provide Update on Phase 3 Trial of Motesanib in Patients With Non-Small Cell Lung Cancer 7
(Date:7/11/2014)... (PRWEB) July 11, 2014 According to ... & Application Market by Communication Technology (ZigBee, Z-Wave, Bluetooth, ... Electronics, Industrial, Automotive & Transportation, Agriculture) & Geography - ... value of Internet of Things market was worth $1029.5 ... Billion by 2020, at an estimated CAGR of 4.08% ...
(Date:7/11/2014)... Presently, disposable medical suppliers call for the ... segment. During the past two decades, the world market ... average 12.5% per year), primarily owing to the importance ... is the largest market for disposable medical supplies in ... second position is held by Europe with a 29% ...
(Date:7/11/2014)... 10, 2014) Obese and overweight firefighters are ... care providers, according to new research from The ... (UTHealth). , National guidelines state that health care ... of maintaining a healthy weight. Firefighters have high ... leading cause of line-of-duty deaths in firefighters. This ...
(Date:7/11/2014)... to repair damage to the anterior cruciate ligament (ACL) -- ... could increase a young athlete,s risk for further injuries, researchers ... aged 8 to 16, who had ACL reconstruction surgery. Of ... their injury, 37 had surgery six to 12 weeks after, ... their injury. The youngsters who had surgery later had ...
(Date:7/11/2014)... Ticket Down is a reliable source for cheap ... CA. Over the years Luke Bryan has been honored by ... he do well at award shows, but each summer, he hits ... tours of the genre and this summer is more of the ... to the popularity and success that is currently entitled to Luke ...
Breaking Medicine News(10 mins):Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 2Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 3Health News:Internet of Things Technology & Application Market Worth $1423.09 Billion by 2020 – New Report by MarketsandMarkets 4Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 2Health News:Global Disposable Medical Supplies Market to See Robust Growth Through Next Decade, According to New TriMark Report Available at MarketPublishers.com 3Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 2Health News:Luke Bryan Tickets Shoreline Amphitheatre in Mountain View, CA: Ticket Down Slashes Ticket Prices for Luke Bryan in Mountain View at the Shoreline Amphitheatre 3
... June 5 The combination of two different chemotherapies ... cancers is not effective against advanced melanoma, according to ... 46th annual meeting of the American Society of Clinical ... we learn something important about the treatment of melanoma," ...
... ... that a less-invasive technique called sentinel node resection is just as safe ... the underarm area, according to a new study being presented today at ... National Surgical Adjuvant Breast and Bowel Project (NSABP) and Allegheny General Hospital ...
... chemotherapy, new drug prolonged lives of some with advanced ... report they prolonged survival for some patients with advanced ... is currently only about six months. , One ... tumors in the majority of lung cancer patients with ...
... drugs approved for treatment of drug-resistant chronic myeloid leukemia ... therapy than the existing front-line medication, according to two ... of Medicine . Separate international phase III ... treatment between the standard-of-care drug imatinib, also known as ...
... CHICAGO - Dasatanib, a medication currently approved as treatment ... quicker, better responses as a first therapy than the ... of Texas MD Anderson Cancer Center. The findings ... American Society of Clinical Oncology today, and published in ...
... early because of supplement,s poor performance , SATURDAY, June ... selenium doesn,t reduce the likelihood of lung cancer recurrence, ... D. Karp, a professor in the department of thoracic/head ... M.D. Anderson Cancer Center, is scheduled to present the ...
Cached Medicine News:Health News:Combination treatment regimen not effective against advanced melanoma 2Health News:Less-invasive Lymph Node Resection Following Breast Cancer Surgery Confirmed as Standard of Care in Eight-year Study Led by AGH Doctors 2Health News:Researchers Report Treatment Headway Against Lung Cancer 2Health News:Researchers Report Treatment Headway Against Lung Cancer 3Health News:Second-line CML drugs evoke faster, better front-line remissions 2Health News:Second-line CML drugs evoke faster, better front-line remissions 3Health News:Second-line CML drug evokes faster response, fewer side effects, pivotal study finds 2Health News:Don't Count on Selenium to Prevent Lung Cancer Recurrence 2
... HYDROLYSER Percutaneous Thrombectomy Catheter is ... for rapid, effective and easy removal ... shunts. The HYDROLYSER catheter provides an ... thrombolytic therapy. ,Compatible with ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
... The AVX catheter is designed ... to 12mm. High-pressure saline jets travel ... sound to create a low pressure ... is drawn into the catheter where ...
Redel Connector 10 Pin...
Medicine Products: